Takeda has outlined plans to reduce around 4,500 roles during its 2026 fiscal year as part of a multiyear restructuring effort aimed at centralizing corporate functions, reducing management layers and simplifying internal processes. The company provided additional details on the initiative during its full-year earnings presentation on May 13.
The restructuring program, described as Takeda’s 2026 “transformation program,” is expected to result in approximately 170 billion Japanese yen ($1.07 billion) in restructuring costs during fiscal 2026. The company said the effort is projected to generate roughly 100 billion yen ($633 million) in gross savings during the year, with annualized savings expected to exceed 200 billion yen ($1.26 billion) by 2028.
The latest round of restructuring follows Takeda’s enterprise-wide efficiency program conducted during 2024 and 2025, which affected more than 4,000 positions over the two-year period. Recently, the company also disclosed plans to cut 634 jobs tied to its U.S. headquarters in Cambridge, Massachusetts, as part of the broader efficiency initiative.
Takeda’s cost-cutting efforts began in 2024 as revenue from attention-deficit/hyperactivity disorder treatment Vyvanse declined following patent expiration and the entry of generic competitors. The company previously said that 2025 would mark the final year of significant generic-related pressures on Vyvanse and is now focusing on upcoming product launches.
For fiscal 2026, which ends in March 2027, Takeda expects full-year revenue of 4.64 trillion Japanese yen ($29.4 billion). The company said this outlook reflects mature portfolio headwinds during a period in which it is shifting toward new launches.
Among Takeda’s leading late-stage assets are narcolepsy treatment oveporexton, polycythemia vera candidate rusfertide and psoriasis medicine zasocitinib. The company said oveporexton and rusfertide are under priority review with the U.S. Food and Drug Administration and could potentially launch commercially in the United States during the second half of 2026. Takeda is also making investments to support a regulatory filing for zasocitinib later this year.
“We are very, very excited about these three launches, and we’re laser-focused on the execution,” CEO-Elect Julie Kim said during Takeda’s earnings conference call with investors.
Kim said Takeda’s transition will unfold in two phases. The first phase, called “Horizon One,” will focus on establishing the three new growth drivers while maintaining the resilience and competitiveness of the company’s core in-line brands. This will be followed by “Horizon Two,” which is intended to introduce another wave of late-stage pipeline assets and maximize revenue from the initial launches.
Kim said Takeda is transitioning to a “new cohort of blockbuster brands” intended to position the company for “long-term profitable growth and patient impact.”
Takeda reported full-year fiscal 2025 revenue of 4.5 trillion Japanese yen ($28.3 billion), representing a 1.7% decline compared with the previous year. The company entered fiscal 2026 with 684.5 billion yen ($4.3 billion) in free cash flow.
Growth and launch products accounted for 51% of Takeda’s yearly revenue, including inflammatory bowel disease drug Entyvio and hereditary angioedema medicine Takhzyro. Combined, the portfolio of growth products generated 2.3 trillion Japanese yen ($14.5 billion), which the company said partially offset the continuing effects of Vyvanse’s generic erosion. Sales of Vyvanse and other products affected by patent expirations declined 43% over the year.
Takeda’s fiscal 2025 earnings conference call marked the final one for outgoing CEO Christophe Weber, who has led the company since 2015 following a 20-year career at GSK. Weber was the first non-Japanese CEO in Takeda’s more than 200-year history. Kim, who joined Takeda in 2019 and has led the company’s U.S. operations since 2022, was selected as CEO as part of what Weber described as a “thoughtful and intentional” succession process.
Takeda has announced plans to reduce approximately 4,500 jobs globally as the pharmaceutical company prepares for a leadership transition and the launch of three important new medicines. The restructuring strategy reflects ongoing efforts by Takeda to improve operational efficiency while strengthening its long-term growth pipeline.
The announcement comes during a critical period for the company as it focuses on innovation, cost management, and future product commercialization.
Large pharmaceutical companies frequently restructure operations to adapt to changing market conditions, rising research costs, and competitive pressures. Workforce reductions are often part of broader efficiency initiatives aimed at reallocating resources toward high-priority therapeutic areas and late-stage product pipelines.
Analysts note that the pharmaceutical sector has become increasingly focused on balancing operational savings with continued investment in innovation and advanced clinical development.
Leadership Changes and Corporate Strategy
Executive leadership transitions can significantly influence a company’s long-term direction. New leadership teams often review research priorities, global expansion strategies, and organizational structures to align future business goals with market opportunities.
In many cases, leadership changes are accompanied by strategic restructuring efforts designed to strengthen profitability and improve commercial execution across international markets.
Future Outlook for Takeda
As Takeda moves through its CEO transition and prepares for key product launches, the company is expected to continue balancing cost management with research investment. The coming years may prove critical in determining how effectively the organization adapts to changing healthcare market demands.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
